Oxford Biomedica (LON:OXB) Reaches New 52-Week High – Time to Buy?

Oxford Biomedica plc (LON:OXB)’s share price reached a new 52-week high on Tuesday . The company traded as high as GBX 671.47 and last traded at GBX 658.20, with a volume of 160733 shares trading hands. The stock had previously closed at GBX 658.37.

Analyst Ratings Changes

A number of analysts have weighed in on OXB shares. Canaccord Genuity Group restated a “buy” rating and issued a GBX 451 price target on shares of Oxford Biomedica in a research note on Tuesday, October 7th. JPMorgan Chase & Co. cut their target price on Oxford Biomedica from GBX 490 to GBX 400 and set a “neutral” rating on the stock in a research report on Tuesday, July 15th. Peel Hunt reiterated a “buy” rating and set a GBX 451 target price on shares of Oxford Biomedica in a research report on Friday, August 1st. Finally, Royal Bank Of Canada lifted their target price on Oxford Biomedica from GBX 800 to GBX 930 and gave the stock an “outperform” rating in a research report on Tuesday, August 26th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Oxford Biomedica presently has an average rating of “Moderate Buy” and a consensus target price of GBX 558.

Oxford Biomedica Price Performance

The stock has a 50-day moving average price of GBX 598.34 and a 200 day moving average price of GBX 441.47. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67. The firm has a market cap of £765.71 million, a price-to-earnings ratio of -17.59 and a beta of 1.09.

Insider Activity at Oxford Biomedica

In related news, insider Roch Doliveux purchased 67,000 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The shares were purchased at an average price of GBX 450 per share, for a total transaction of £301,500. Also, insider Dame Kay Davies sold 4,563 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of GBX 500, for a total value of £22,815. 41.90% of the stock is currently owned by insiders.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.